Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540995 · ClinicalTrials.gov registry record · Phase 1
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00540995 is a Phase 1 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00540995, a Phase 1 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving intensity-modulated radiation therapy together with busulfan and etoposide before a transplant may stop this from happening. PURPOSE: This phase I/II trial is studying the side effects and best dose of intensity-modulated radiation therapy when given together with busulfan and etoposide followed by a donor stem cell transplant and to see how well it works in treating patients with advanced myeloid cancer.
Interventions
- RADIATION intensity-modulated radiation therapy
- DRUG etoposide
- PROCEDURE allogeneic hematopoietic stem cell transplantation
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-06-11 |
| Est. Completion | 2011-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540995
The ClinicalTrials.gov registry entry for NCT00540995 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT00540995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00540995 about?
NCT00540995 is a clinical study titled "Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer". RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells...
What is the current status of trial NCT00540995?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-06-11. Estimated completion is 2011-08-09.
What interventions are being tested in trial NCT00540995?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), etoposide (DRUG), allogeneic hematopoietic stem cell transplantation (PROCEDURE), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00540995?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.